2 results
Search Results
Now showing 1 - 2 of 2
Article Main Outcomes of the Diyal-Tr Study: Regional\rdifferences of Mortality and Morbidity in Chronic\rhemodialysis Patients(Aves, 2022) Kızılırmak, Pınar; Ecder, Süleyman Tevfik; Ateş, Kenan; Arıcı, Mustafa; Sezer, Siren; Kaptanoğulları, Hakan; Arınsoy, Selim Turgay; Ecder, Tevfik; Arinsoy, TurgayObjective: Variations in care at national or global level may have an impact on the prognosis of patients on chronic hemodialysis.\rWe aimed to describe regional differences in all-cause mortality or cardiovascular morbidity in chronic hemodialysis\rpatients in Turkey.\rMethods: We enrolled 2461 patients who were initiated chronic hemodialysis in 93 centers in Turkey between January 27,\r2017, and February 09, 2018. We included 2-year follow-up data of 1877 patients in this prospective study. The primary\routcome, the rate of composite endpoint of all-cause mortality or cardiovascular morbidity, was compared between geographical\rregions. Secondary outcomes were the rates of hospitalization and infections.\rResults: In total, 552 patients (29.4%) developed the primary outcome. The highest and lowest rates of primary outcome\roccurred in the Mediterranean (34.5%) and Southeastern (26.5%) & Central Anatolian regions (26.5%), respectively, with no\rsignificant differences across regions (P = .82). Hospitalization events were detected in 377 patients (20.1%). The highest\rrate of hospitalization was detected in the Black Sea region (33.8%), and the lowest (7.6%) in the Southeastern region. The\rregions did not differ in hospitalization rates (P = .88). Infections occurred in 11.3% (n = 212) of the patients. The highest and\rlowest rates of infections occurred in the Aegean (18.2%) and the Southeastern (2.9%) regions, respectively. We detected\rsignificant difference between geographic regions (P = .02).\rConclusions: Our study showed that almost 3 in every 10 chronic hemodialysis patients reached the primary endpoint\rof all-cause mortality/cardiovascular morbidity during the 2 years of follow-up. The occurrence of this outcome does not\rseem to exhibit geographical variation across the country.Other Current Induction Therapy Strategies and Anti-T Lymphocyte Globulin Usage in Kidney Transplantation: Consensus-Based Recommendations by a Turkish Expert Panel(Aves, 2024) Çakır, Ülkem; Dinçkan, Ayhan; Karadoğan, Nayim; Keven, Kenan; Koçak, Hüseyin; Koç, Serkan Kubilay; Yıldız, Alaattin; Turkmen, Aydin; Töz, Hüseyin; Sezer, SirenThis advisory committee convened to review national and global kidney transplantation dynamics and provide recom- mendations on the use of anti-T lymphocyte globulin (ATLG) for prevention and treatment of rejection after allogeneic kidney transplantation. A critical evaluation of 6 relevant articles released up to October 2022 was performed to reveal their importance in clinical practice. Additionally, 27 key questions on the indication, dosage of ATLG, and risk stratification were used for the Delphi technique with 8 members of the Turkish Society of Nephrology including 5 kidney transplanta- tion (KTx) subcommittee members and a surgeon experienced in solid organ transplantation. The committee declared that Türkiye had great potential in KTx; however, increase in transplantation would be possible in the case of raise in the deceased donor transplantation. As a consensus, ATLG was strongly recommended for induction and rejection treatment. Also, committee members recommended the safe dosage range in steroid resistant acute rejection as 2.5-3 mg/kg daily for 5-7 days, and the median of preferred dosage in induction sounded as 2-2.5 mg/kg daily for 3 days in intermediate risk state. Additionally, post-transplant infection and malignancy cases due to immunosuppression were much rarely encoun- tered than they were in the past.
